Breaking New Ground in the Treatment of Schizophrenia

We are driven to improve the health and well-being of all people affected by neuropsychiatric disorders.

About Us

We are committed to leading innovation in the neuropsychiatric disease field by advancing programs that target selective CNS circuits in the brain with clinically validated mechanisms of action. We believe this approach will help our therapies achieve better efficacy and tolerability, with the goal to deliver improved outcomes for patients.

Our lead product, EM-221, is a potentially groundbreaking advancement in schizophrenia treatment, with a new, differentiated PDE10A inhibitor.

Our Pipeline

We are building a pipeline-in-a-product around EM-221. EM-221 is an innovative product that targets the phosphodiesterase 10A enzyme, uniquely concentrated in the brain’s striatum, to enhance cyclic nucleotide signaling and balance dopamine pathways. Unlike traditional antipsychotics, it offers the potential to address not only the positive symptoms like hallucinations but also the challenging negative symptoms—such as social withdrawal, blunted emotions and difficulty planning—that often persist untreated.

Preclinical

Compound

Indication

(PDE10A inhibitor)

Phase 1

EM-221

Phase 2

Phase 3

Study Start

Schizophrenia

2H 2025

- Parkinson's
- Alzheimer's
(with agitation aggression/psychosis)
- Treatment resistant depression
- Bipolar Disorder
- Tourette's

Expansion opportunities: EM-221

CNS indications where PDE10A inhibition can be effective

Developed through years of rigorous research, this breakthrough heralds a new era of hope, aiming to improve overall quality of life for those affected by schizophrenia with a novel mechanism that’s both precise and promising.

In The News

Coming Soon.